Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › New York › Syracuse
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Syracuse, NY keessatti
Qorannoo 15 Kansara Qara'a Non-Small Cell f Syracuse fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Namoota walitti qabaa jiraSadarkaa 3
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · Miili 4 fagaatti
- Hematology Oncology Associates of CNY at Camillus, Camillus · Miili 8 fagaatti
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- State University of New York Upstate Medical University, Syracuse
- SUNY Upstate Medical Center-Community Campus, Syracuse
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · Miili 4 fagaatti
- fi 1 dabalataa
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Namoota walitti qabaa jiraSadarkaa 2
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Hill Radiation Oncology, Syracuse
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Namoota walitti qabaa jiraSadarkaa 3
- SUNY Upstate Cancer Center ( Site 0140), Syracuse
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse · Miili 4 fagaatti
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #76, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, East Syracuse · Miili 4 fagaatti
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Hematology-Oncology Associates of CNY, East Syracuse · Miili 4 fagaatti
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- SUNY Upstate Medical University, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, East Syracuse · Miili 4 fagaatti
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Syracuse
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- SUNY Upstate Medical University, Syracuse
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, East Syracuse · Miili 4 fagaatti
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- State University of New York Upstate Medical University, Syracuse
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- SUNY - Upsate Medical Centre, Syracuse
GEMINI-NSCLC: NSCLC Biomarker Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Hematology Oncology Associates of Central New York, East Syracuse · Miili 4 fagaatti
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Syracuse keessatti
- Saree (Gosoota Hunda)Qorannoo 9
- Kansarii ProstateQorannoo 9
- Kansara Baadii Harkaa Non-Muscle InvasiveQorannoo 8
- Kansarii OvariiQorannoo 7
- Kansa EndometiriyaaliiQorannoo 7
- ObesityQorannoo 6
- Dhibee QaraQorannoo 6
- Kansarii ColorectalQorannoo 5
- Degenereshinii MakulaariiQorannoo 5
- Leukemia Myeloidii HamaaQorannoo 5
- Sukkaraa Gosa 2Qorannoo 5
- LupusQorannoo 5
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.